Cargando…

Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells

Macrophage migration inhibitory factor (MIF) is involved in protein‐protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active site. Here, we use this site to develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Zhangping, Song, Shanshan, Chen, Deng, van Merkerk, Ronald, van der Wouden, Petra E., Cool, Robbert H., Quax, Wim J., Poelarends, Gerrit J., Melgert, Barbro N., Dekker, Frank J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362126/ https://www.ncbi.nlm.nih.gov/pubmed/34018657 http://dx.doi.org/10.1002/anie.202101864

Ejemplares similares

4‐Iodopyrimidine Labeling Reveals Nuclear Translocation and Nuclease Activity for Both MIF and MIF2
por: Xiao, Zhangping, et al.
Publicado: (2021)

Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione Derivative Inhibits d-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer Cells
por: Xiao, Zhangping, et al.
Publicado: (2022)

7-Hydroxycoumarins Are Affinity-Based Fluorescent Probes for Competitive Binding Studies of Macrophage Migration Inhibitory Factor
por: Xiao, Zhangping, et al.
Publicado: (2020)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Macrophage migration inhibitory factor family proteins are multitasking cytokines in tissue injury
por: Song, Shanshan, et al.
Publicado: (2022)

Allosteric Inhibitors of Macrophage Migration Inhibitory Factor (MIF) Interfere with Apoptosis-Inducing Factor (AIF) Co-Localization to Prevent Parthanatos
por: Chen, Deng, et al.
Publicado: (2023)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2022)

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
por: Ruffilli, Camilla, et al.
Publicado: (2022)

Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
por: Tashima, Toshihiko
Publicado: (2023)

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
por: Bond, Michael J., et al.
Publicado: (2021)

Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
por: Goracci, Laura, et al.
Publicado: (2020)

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
por: Haid, Robin Thomas Ulrich, et al.
Publicado: (2023)

Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)
por: Baker, India M., et al.
Publicado: (2022)

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020)

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
por: Vicente, André T. S., et al.
Publicado: (2022)

Genetic regulation of gene expression of MIF family members in lung tissue
por: Florez-Sampedro, Laura, et al.
Publicado: (2020)

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
por: Hu, Mingxing, et al.
Publicado: (2020)

Cell Morphological Profiling Enables High-Throughput Screening for PROteolysis TArgeting Chimera (PROTAC) Phenotypic Signature
por: Trapotsi, Maria-Anna, et al.
Publicado: (2022)

Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
por: Manda, Sudhakar, et al.
Publicado: (2020)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
por: Liu, Li, et al.
Publicado: (2022)

Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras
por: Zhao, Chunlong, et al.
Publicado: (2022)

Creation of RANKL mutants with low affinity for decoy receptor OPG and their potential anti‐fibrosis activity
por: Wang, Yizhou, et al.
Publicado: (2019)

Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
por: Darwish, Salma, et al.
Publicado: (2022)

D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling
por: Song, Shanshan, et al.
Publicado: (2021)

Shining a Light on Proteolysis Targeting Chimeras
por: Teichmann, Ellen, et al.
Publicado: (2019)

Proteolysis-targeting chimeras and their implications in breast cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2021)

The clinical advances of proteolysis targeting chimeras in oncology
por: Xie, Hao, et al.
Publicado: (2021)

HaloTag‐Targeted Sirtuin‐Rearranging Ligand (SirReal) for the Development of Proteolysis‐Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)
por: Schiedel, Matthias, et al.
Publicado: (2020)

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
por: Lebraud, Honorine, et al.
Publicado: (2016)

Assays and technologies for developing proteolysis targeting chimera degraders
por: Liu, Xingui, et al.
Publicado: (2020)

Tuning Enzyme Activity for Nonaqueous Solvents: Engineering an Enantioselective “Michaelase” for Catalysis in High Concentrations of Ethanol
por: Guo, Chao, et al.
Publicado: (2020)

PvdQ Quorum Quenching Acylase Attenuates Pseudomonas aeruginosa Virulence in a Mouse Model of Pulmonary Infection
por: Utari, Putri D., et al.
Publicado: (2018)

Computer aided drug design in the development of proteolysis targeting chimeras
por: Tunjic, Tin M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b4pcousn2aaridumps1hfurkqu